You may be weighing whether to ask a doctor about ADHD, and advice is coming from every side. You may have heard that your child will grow out of it. You may have been told that a psychiatric diagnosis goes on a record that follows a child for years, or that ADHD medicine damages the brain and leads to addiction. If your family has roots in Korea or elsewhere in Asia, you may also have read that Asian American children are diagnosed with ADHD less often than other children.
This column asks what the research says about each worry and what the lower US diagnosis rate does and does not mean. It also shows how Korea handles medical records and what Korean figures look like. It does not say any country does better.
How much less often are Asian children diagnosed in the US?
A 2021 study in JAMA Network Open (Shi and colleagues) analyzed claims from a US commercial insurance database for 238,011 children born from 2006 to 2012. By age 12, an estimated 6.08% of Asian children had an ADHD diagnosis, compared with 11.76% of Black children and 14.19% of White children. After adjusting for sex, region and household income, the hazard ratio for Asian children was 0.48, meaning new diagnoses appeared at about half the pace seen in White children.
Among diagnosed children, Asian and Hispanic children were less likely to receive medication than White and Black children, though Asian children's psychotherapy rate was not significantly lower. The authors wrote that treatment gaps "may also reflect" parents' care-seeking preferences.
Other data agree. In the 2022 National Survey of Children's Health (45,169 children aged 3 to 17), parents reported that a doctor had ever diagnosed ADHD in 4.0% of Asian children and 11.9% of White children (Danielson and colleagues, 2024).
Does a lower diagnosis rate mean children are being missed?
The study cannot answer that. Its authors had no data on children's symptoms, so they could not say whether the gap reflects underdiagnosis or overdiagnosis. They also noted that insured children may not represent all US children.
A 2024 narrative review in the Journal of Attention Disorders (Feng, O'Neill and Rostain) lists factors that may contribute to the low estimates. They include more inattentive-type ADHD among Chinese, Malaysian and Indian children, racial bias and the "model minority" myth, differences in how classrooms spot ADHD, mental health stigma, parents who see ADHD as misbehavior, and academic support that may mask difficulties. These are candidates, not proven causes, and the review warns that findings from Asia may not carry over exactly to Asian Americans.
What do studies of Asian families say about stigma?
The same review says stigma about psychiatric medicine is widely reported in Asia and is likely similar among Asian American parents. It adds that they may share other American parents' fear that medicine will make children "zombies."
The direct evidence is thin, and we did not find an ADHD study of Korean American parents. Seven focus groups with 31 Korean parents living in New Zealand (2022) named barriers to children's mental health care, including social stigma, denial or normalizing of a child's behavior, and mistrust of public services. It covered child mental health in general, not ADHD alone.
In a 2025 study of 28 Chinese Canadian and 28 European Canadian parents, the Chinese Canadian parents began with less ADHD knowledge and more stigma. A pamphlet raised their knowledge and acceptance of medication more than the other group's, but stigma scores rose in both groups. None of these studies describes Asian parents as a whole.
Do children grow out of ADHD?
The American Academy of Pediatrics (AAP) 2019 guideline says most children with ADHD continue to have symptoms and impairment through adolescence and into adulthood. Hyperactive and impulsive symptoms tend to decline in the teen years, while inattention tends to persist. How many adults still have ADHD depends on how you count, as the table shows.
| Study | What was counted | Result |
|---|---|---|
| Faraone et al., 2006 (meta-analysis) | Full ADHD at about age 25 | About 15% |
| Same study | Full ADHD plus partial remission | About 65% |
| Sibley et al., 2022 (558 children, up to 16 years) | Recovered and stayed in remission | 9.1% |
| Same study | Some leftover symptoms as young adults | About 90% |
Sibley and colleagues note that the common estimate that about half of children outgrow ADHD usually rests on a single check-in. Their children came from one US treatment study, the Multimodal Treatment Study of ADHD (MTA). In Korea, the government's policy magazine K-Gonggam (K-공감) named thinking that ADHD improves on its own as a typical misconception in 2023, though that is the magazine's view, not a survey of parents.
Does a diagnosis stay on a record in Korea?
Records are kept. Korea's Medical Service Act (의료법) requires medical professionals to write a patient's main symptoms, diagnosis and treatment into a treatment record (진료기록부), and the enforcement rule sets its retention period at 10 years.
By default, only the patient can see a patient's records: doctors, clinic heads and staff may not let anyone else view or copy them. The act then lists exceptions where access must be allowed, including:
- a family member with proof of kinship and the patient's signed consent (not needed if the patient is under 14)
- the National Health Insurance Service (국민건강보험공단) and the Health Insurance Review and Assessment Service (건강보험심사평가원), for reviewing and paying claims
- criminal procedure
- the Military Manpower Administration (병무청), when it asks a medical institution for records to confirm illness or disability for conscription exams (병역판정검사) or service-record management
The list is longer, and a proviso lets a doctor decline if the doctor judges refusal unavoidable for the patient's treatment. As we read it, nothing in the list tells a clinic to open a child's records to a school or an employer. What you hand over yourself, such as a diagnosis certificate, is a separate matter. This summary of the law in force in October 2026 is not legal advice.
Does ADHD medicine hurt the brain?
A 2025 umbrella review (a review of reviews) in the BMJ (Gosling and colleagues) found that in the short term, medicines including methylphenidate, amphetamines and atomoxetine reduced ADHD symptoms in children and teens by medium to large amounts, with moderate to high certainty. It found no high-certainty long-term evidence for any treatment, drug or not.
On the brain, the World Federation of ADHD's 2021 consensus statement reports that medication had no effect on brain structure across 4,180 people with ADHD in 36 cohorts. A 2014 meta-analysis (Coghill and colleagues) found methylphenidate beat placebo on all five cognitive measures it pooled. These are scan and short-term task results, not studies of intelligence or school grades.
What about growth and addiction?
The AAP guideline says the MTA found a more lasting effect of stimulants on growth than earlier studies had: about 1 to 2 cm below predicted adult height, most noticeably with higher, steadier doses. The effect faded by the third year, but no catch-up growth was seen. The UK's National Institute for Health and Care Excellence (NICE) tells clinicians to measure height every 6 months in children and teens taking ADHD medicine.
A 2026 study of Korean National Health Insurance Service data in JAMA Network Open (Song and colleagues) compared adults diagnosed with ADHD at ages 6 to 11 with adults without ADHD. Average height was about the same (167.8 versus 167.9 cm, not a significant difference), but average BMI was higher (24.3 versus 23.3), and those who took methylphenidate had slightly higher odds of short stature (adjusted odds ratio 1.08). The authors called the height difference clinically small and urged regular growth monitoring.
On addiction, a 2013 meta-analysis in JAMA Psychiatry (Humphreys and colleagues) pooled 15 studies with 2,565 participants and found comparable substance use outcomes in children with and without stimulant treatment history. The authors suggested that treatment neither protects against nor raises the risk of later substance use disorders. A 2014 Swedish register study (Chang and colleagues) found no link between ADHD medication and higher substance abuse. Both are observational.
Misuse is a separate issue. The AAP calls diversion, meaning use of the medicine for something other than its medical purpose, a special concern among adolescents. NICE advises clinicians and parents to keep watching for misuse and diversion as a child's age and circumstances change.
What do the numbers look like in Korea?
Korean studies estimate childhood ADHD in very different ways.
| Source | Sample and method | Finding |
|---|---|---|
| Cho et al., 2009 | 2,493 elementary students in Seoul | 5.90% full ADHD |
| Kim et al., 2017 | Ages 7 to 12; screening, then clinical interviews | 8.5% |
| National survey, Kim et al., 2025 | 6,275 children and teens aged 6 to 17; home interviews in 2022 and 2023 | 0.6% childhood ADHD |
| Insurance claims, Seo et al., 2022 | Patients up to age 18 with ADHD as the main diagnosis | 0.53% in 2008, 0.78% in 2018 |
Because ages, years, tools and definitions differ, and a claims count includes only children who reached a doctor, these figures cannot be turned into a "percent treated." The claims study's authors found the diagnosed rate rising but low compared with the global average, and inferred that many children with ADHD in Korea remain undiagnosed or untreated. That is their inference, not a measured rate.
Claims also move with billing rules. After an April 2013 change let psychiatric counseling without medication be billed under a general health consultation code, child ADHD claims fell until 2015. The authors attribute the dip to that change and a campaign against overdiagnosis, and suggest many families chose the general code to avoid stigma.
The short version
- In US insurance data, an estimated 6.08% of Asian children were diagnosed with ADHD by age 12, versus 14.19% of White children; the authors could not say whether that reflects underdiagnosis or overdiagnosis.
- Direct studies of stigma and beliefs in Asian families are small and come from different groups, so none describes Asian parents as a whole.
- The AAP says most children with ADHD keep symptoms into adulthood: hyperactivity tends to fade, and inattention tends to stay.
- In Korea, treatment records are kept for 10 years and shown only to the patient by default, with exceptions the law lists.
- ADHD medicine shows short-term symptom benefit, no change in brain structure, small height differences to monitor and, in observational studies, no rise in later substance problems. Misuse still needs watching.
This column is based on the studies and guidelines named above, Korea's Medical Service Act on the government's law site, and a 2023 K-Gonggam article, all checked October 2026. It is general information, not medical advice — talk to your child's doctor (or the relevant office) before making decisions.